Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy - PubMed (original) (raw)
. 2010 Apr 15;116(8):1909-17.
doi: 10.1002/cncr.24905.
Affiliations
- PMID: 20162716
- DOI: 10.1002/cncr.24905
Free article
Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy
Derek R Wilke et al. Cancer. 2010.
Free article
Abstract
Background: Combined long-term androgen deprivation (LTAD) and radiation conveys a prostate cancer-specific survival advantage over combined short-term androgen deprivation (STAD) and radiation. The seminal question is whether or not the gains are worth the adverse effects of LTAD with respect to patient preferences.
Methods: Preferences for LTAD compared with STAD were elicited by direct patient interview using the probability trade-off method. "Time trade-off utilities" (TTOu) for erectile dysfunction and osteoporosis were elicited using the time trade-off method. Participants' current prostate cancer-specific health state was assessed using the Patient-Oriented Prostate Utility Scale-Psychometric. Participants' current sexual function was assessed using the International Index of Erectile Function (IIEF).
Results: All participants were willing to trade survival rather than undergo LTAD compared with STAD. The mean minimally required increment in prostate cancer-specific survival (MRIS) was 8.2%. The mean TTOu for impotence was 0.78, and the mean TTOu for osteoporosis was 0.71. The MRIS was correlated with the Sexual Desire domain score of the IIEF (Spearman rank-correlation coefficient, r = 0.50; P<.0001).
Conclusions: Patients desired more prostate cancer-specific survival than what was afforded by LTAD and radiotherapy compared with STAD and radiotherapy.
(c) 2010 American Cancer Society.
Similar articles
- Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A, Watkins-Bruner D, Brereton H, Feigenberg S, Hanks G. Konski A, et al. Cancer. 2006 Jan 1;106(1):51-7. doi: 10.1002/cncr.21575. Cancer. 2006. PMID: 16323171 - Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP. Teloken PE, et al. J Urol. 2007 Dec;178(6):2521-5. doi: 10.1016/j.juro.2007.08.007. Epub 2007 Oct 15. J Urol. 2007. PMID: 17937948 - Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Feigenberg SJ, et al. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):397-405. doi: 10.1016/j.ijrobp.2004.10.021. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890581 - Endocrine treatment of prostate cancer.
Tammela T. Tammela T. J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review. - [Association of radiotherapy and hormonotherapy in locally advanced prostate cancer].
Quero L, Wong-Hee-Kam S, Rivera S, Hennequin C. Quero L, et al. Bull Cancer. 2012 Jul;99 Suppl 1:S30-6. doi: 10.1684/bdc.2012.1567. Bull Cancer. 2012. PMID: 22516590 Review. French.
Cited by
- Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT).
Shah S, Pepin A, Forsthoefel M, Burlile J, Collins BT, Simeng S, Aghdam N, Collins S. Shah S, et al. Cureus. 2023 Aug 31;15(8):e44440. doi: 10.7759/cureus.44440. eCollection 2023 Aug. Cureus. 2023. PMID: 37791195 Free PMC article. - Patients' Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer.
De B, Lowenstein LM, Corrigan KL, Andring LM, Kuban DA, Cantor SB, Volk RJ, Hoffman KE. De B, et al. MDM Policy Pract. 2022 Nov 15;7(2):23814683221137752. doi: 10.1177/23814683221137752. eCollection 2022 Jul-Dec. MDM Policy Pract. 2022. PMID: 36405544 Free PMC article. - The Evolution of and Risk Factors for Neck Muscle Atrophy and Weakness in Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy: A Retrospective Study in an Endemic Area.
Zhang LL, Mao YP, Zhou GQ, Tang LL, Qi ZY, Lin L, Yao JJ, Ma J, Lin AH, Sun Y. Zhang LL, et al. Medicine (Baltimore). 2015 Aug;94(31):e1294. doi: 10.1097/MD.0000000000001294. Medicine (Baltimore). 2015. PMID: 26252307 Free PMC article. - The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation.
Matza LS, Boye KS, Feeny DH, Bowman L, Johnston JA, Stewart KD, McDaniel K, Jordan J. Matza LS, et al. Eur J Health Econ. 2016 Nov;17(8):979-990. doi: 10.1007/s10198-015-0740-7. Epub 2015 Nov 26. Eur J Health Econ. 2016. PMID: 26611792 Free PMC article. - Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.
King MT, Viney R, Smith DP, Hossain I, Street D, Savage E, Fowler S, Berry MP, Stockler M, Cozzi P, Stricker P, Ward J, Armstrong BK. King MT, et al. Br J Cancer. 2012 Feb 14;106(4):638-45. doi: 10.1038/bjc.2011.552. Epub 2012 Jan 24. Br J Cancer. 2012. PMID: 22274410 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical